Skip to main content
. Author manuscript; available in PMC: 2023 May 30.
Published in final edited form as: J Thorac Cardiovasc Surg. 2022 Jan 23;164(5):1327–1337. doi: 10.1016/j.jtcvs.2022.01.019

FIGURE 3.

FIGURE 3.

Distribution of 30-day Clavien–Dindo postoperative morbidity scores for Nivolumab With or Without Ipilimumab in Treating Patients With Previously Untreated Stage I-IIIA Non–Small Cell Lung Cancer (NEOSTAR) and The Immunogenomic Profiling of Non–Small Cell Lung Cancer (ICON) patients. Clavien–Dindo classification 1 = deviation from normal postoperative course without the need for intervention; 2 = complication requiring pharmacological intervention including blood transfusion; 3 = complication requiring invasive intervention; 4 = complication requiring intensive care unit care; and 5 = death. NEOSTAR-N, NEOSTAR-neoadjuvant nivolumab; NEOSTAR-NI, NEOSTAR-neoadjuvant nivolumab with ipilimumab; ICON-Chemo, ICON-neoadjuvant chemotherapy; ICON-Upfront, ICON-upfront surgical resection.